1998
DOI: 10.1007/s002280050498
|View full text |Cite
|
Sign up to set email alerts
|

Under-reporting of adverse drug reactions

Abstract: The under-reporting rate of ADRs is considerable, though not homogeneous for the different cases. This should be taken into account when comparing adverse effects (AEs) for different drugs. Under-reporting seems to be positively selective, as it involves mainly the less severe and better-known effects, preserving the value of spontaneous reporting for signal detection.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
28
0
1

Year Published

1999
1999
2019
2019

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 201 publications
(29 citation statements)
references
References 0 publications
0
28
0
1
Order By: Relevance
“…This has been reinforced by many studies carried out in developed and developing countries [1,3], which have encompassed attitudes, perceptions and barriers towards ADR reporting. However, ADR reporting is considered an important component of the drug safety monitoring framework [4].…”
Section: Problem Backgroundmentioning
confidence: 99%
See 1 more Smart Citation
“…This has been reinforced by many studies carried out in developed and developing countries [1,3], which have encompassed attitudes, perceptions and barriers towards ADR reporting. However, ADR reporting is considered an important component of the drug safety monitoring framework [4].…”
Section: Problem Backgroundmentioning
confidence: 99%
“…Different obstacles to detecting and reporting ADRs were proposed by Inman in the mid-eighties [3] and have since been mentioned in numerous studies [1]. Fear of litigation and fear of appearing ridiculous were reported as two of these barriers.…”
Section: Problem Backgroundmentioning
confidence: 99%
“…Healthcare systems have traditionally relied on patient and clinician self-reports, prescription-event monitoring and case-control studies. These approaches capture serious and unexpected ADRs, whilst minor to moderate ADRs are typically less well reported [26] but remain burdensome to service users. Despite the advantages of service user ADR reporting [27], under-reporting is widely recognised: in a clinical trial only 1.5–5.1% (5/328-11/216) of ADR-related problems were spontaneously reported to physicians, increasing to 29–49% (96/328-105/216) when a questionnaire on specific known ADRs was administered [28], and the overall ADR reporting rate may be around 1% [29].…”
Section: Introductionmentioning
confidence: 99%
“…These reports are not exhaustive and are known to suffer from underreporting bias [9,10]. One can therefore reasonably consider that conventional pharmacovigilance data (i) does not encompass all ADRs and (ii) provides little information on ADEs.…”
Section: Introductionmentioning
confidence: 99%